
    
      A prospective, open-label, multicentre, pharmacokinetic study conducted in the UK hospital.
      Potential eligible patients will have received a 1 gram IV dose of TXA at the scene of the
      injury or on arrival in hospital and a second dose is clinically indicated.
    
  